Levofloxacin should be the first choice for antibacterial prophylaxis

Article

Levofloxacin 0.5% eye drops should be the first choice for antibacterial prophylaxis and treatment, according to Professor P. Asbell of the Mount Sinai School of Medicine, USA.

Levofloxacin 0.5% eye drops should be the first choice for antibacterial prophylaxis and treatment, according to Professor P. Asbell of the Mount Sinai School of Medicine, USA.

Professor Asbell, speaking at the Santen lunchtime symposium, reported on a multicentre study aimed at determining the prevalence of resistance among isolates of various bacterial pathogens against antibiotics obtained from patients with eye infections in Germany.

The study was conducted at 35 sites and collected a total of 1,470 ocular isolates between June and November of 2004. Bacteria were identified and EUCAST break points (susceptible - intermediate - resistant) were applied where available. Susceptibility against eight approved antibiotics, with oxacillin as standard, were examined: levofloxacin, ofloxacin, ciprofloxacin, kanamycin, chloramphenicol, erythromycin, colistin and gentamicin.

The results showed that levofloxacin and chloramphenicol provided the best resistance against streptococcus viridans, gentamicin and erythromycin were most resistant to haemophilus influenzae and that levofloxacin and ciprofloxacin were the first choice against pseudomonas aeruginosa.

The results suggest that levofloxacin offers the broadest spectrum of activity against ocular infections. Furthermore, in a separate study in the USA TRUST (Tracking Resistance in the USA Today), the antibiotic maintained this spectrum over a nine year period. The antibiotic is a third generation quinolone that is highly active against ocular pathogens. It is hydrophilic and lipophillic and penetrates well into the anterior chamber.

Professor Asbell concluded that levofloxacin offers the best resistance profile and should be a first choice for antibacterial prophylaxis and treatment.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.